Anti-infective Agents : Antiretroviral Agents
ORETR1 “Retrovir capsule” 100 mg/cap
適應症：與其他抗反轉錄病毒併用治療後天性免疫缺乏症候群（AIDS）或與其有關之症狀（ARC, AIDS RELATED COMPLEX），受到人類免疫缺乏病毒（HIV）感染沒有症狀或只有初期輕度症狀而CD4T淋巴球數目小於 500/MM3病人的治療
Usual dose: HIV infection, 600 mg/day ORALLY in divided doses
Dose adjustment:
Renal impairment: CrCl 15 mL/min or greater, no dose adjustment necessary; CrCl less than 15 mL/min (maintained on hemodialysis or peritoneal dialysis), 100 mg ORALLY or 1 mg/kg IV every 6 to 8 hours.
Hepatic impairment: reduction in daily dose or extension of dosing interval may be necessary.
Anemia: (Hb less than 7.5 g/dL or decline greater than 25% from baseline) may require discontinuation of therapy until recovery of marrow is evident.
Neutropenia: (granulocyte count less than 750 cells/mm(3) or decline greater than 50% from baseline) may require discontinuation of therapy until recovery of marrow is evident.
Contraindication:
History of potentially life-threatening hypersensitivity reactions (eg, anaphylaxis, Stevens-Johnson syndrome) to zidovudine or any components of the formulations
Adverse effect:
Common:Loss of appetite, nausea, vomiting, cough, fever, malaise.
Serious: Lactic acidosis, increased serum lipase level, serum amylase raised, anemia, granulocytopenic disorder, neutropenia, pancytopenia, thrombocytopenia, hepatomegaly, hepatomegaly, with steatosis; immune reconstitution syndrome, myositis.